| 13 February 2018

Foundation Fighting Blindness and ProQR enter into partnership for Usher's Type 2A

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12

Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.


| 20 December 2017

A message from our president

http://www.retina-international.org/

The Food and Drug Administration (FDA) in the United States approved the first gene therapy to treat an inherited disease on Tuesday December 19th 2017. Although a gene therapy was approved for an ultra-rare disease in Europe a number of years ago and the FDA approved two gene therapies already this year, one for a form of leukaemia and one for a form of lymphoma, this is the first time such a therapy has been approved for an inherited retinal dystrophy (IRD) and marks a new era of hope for our community as a whole.


| 29 October 2017

Basic Science Course in Ophthalmology, Columbia University

Since 1941, the Edward S. Harkness Eye Institute at the Columbia University Department of Ophthalmology has offered an ophthalmology basic science course. While the focus of the course is resident training, it has also proven useful for the visual sciences community as a whole. Coursework examines the fundamentals of vision and emphasizes how these basic principles relate to patient care.

Read more!


| 11 October 2017

Study shows -Avoidable Blindness -Set to Increase in Future

On World Sight Day, eye care organisations around the world take note of new data that shows that global eye care efforts are at serious risk of being overwhelmed—unless we act now.

New data published in the Lancet Global Health shows that decades of declining “avoidable blindness”—those with uncorrected refractive errors and cataract—is plateauing, and is projected to increase between 2015 and 2050.


| 10 October 2017

Industry News: Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

Novartis has reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 patients with neovascular age-related macular degeneration (nAMD) across 400 centres worldwide.


| 02 October 2017

NEI Awards Prize for - Retina in a Dish Competition

NEI 3-D Retina Organoid Challenge spurs next-generation models to study blinding diseases and test therapies

A proposal to create a living model of the human retina, the light-sensitive tissue at the back of the eye, won $90,000 in the National Eye Institute (NEI) 3-D Retina Organoid Challenge (3-D ROC). The NEI 3-D ROC is an initiative that seeks to design human retinas from stem cells. Erin Lavik, Sc.D., at the University of Maryland, Baltimore County, led the awarded team. The NEI is part of the National Institutes of Health.


| 24 August 2017

Scientific Events: A Symposium in honor of Dr. Gustavo Aguirre FARVO, University of Pennsylvania , November 16th, 2017

A Symposium in honor of Dr. Gustavo Aguirre, recipient of the 2017 Proctor Medal, Association for Research in Vision and Ophthalmology (ARVO) will take place on Thursday November 16, 2017; 1:00pm—6:00pm at the School of Veterinary Medicine, University of Pennsylvania Please visit http://TRRaTConference.website2.me

Attendance is free but registration is essential to secure a place.


| 24 August 2017

Industry News: MeiraGTx Provides Clinical Trial Updates for X-Linked Retinitis Pigmentosa and Achromatopsia Gene Therapy Programs

 MeiraGTx, a New York and London based gene therapy company, have announced the first patient in its clinical study for X-Linked Retinitis Pigmentosa (XLRP) was treated at Moorfields Eye Hospital in London.  This clinical study is the first-in-man Phase I/II dose escalation study of AAV2/5-hRKp.RPGR, MeiraGTx’s AAV-mediated gene therapy for XLRP caused by mutations in the RP GTPase regulator gene (RPGR).


| 09 August 2017

Retina International Symposium: EURetina 2017

Retina International will host its annual EURetina Symposium from 9am to 10.30am on Thursday September 7th in room 124 of the Barcelona Convention Centre.

The symposium will feature presentations on the European Reference Network for Rare Eye Disease (ERN-EYE), results from a recent study on the Economic Burden of Blindness in Europe, Patient Reported Outcome Measures for the retina and an introduction to the Retina International toolkit on genetic testing.

Join Our Mailing List